




Group	Day 32	Mean Tumor Volume (mm ³)	% TGI	CR (%)	PR(%)
Group 1- Vehicle, QD		1353.78			
Group 2- Cetuximab 3mg/kg (IP, BIW) **		487.05	64	0/10 (0)	0/10 (0)
Group 3- Compound 1 30mg/kg, QD ***		370.18	73	0/10 (0)	0/10 (0)
Group 4- Compound 1 100mg/kg, QD ****		103.11	92	0/10 (0)	10/10 (100)
Group 5- Compound 1 30mg/kg (PO, QD) + Cetuximab 3mg/kg (IP, BIW) ****, #		73.05	95	3/10 (30)	7/10 (70)
Group 6- Compound 1 100mg/kg (PO, QD) + Cetuximab 3mg/kg (IP, BIW) ****, # &		13.48	100	10/10 (100)	0/10 (0)

FIG. 1




FIG. 2





FIG. 3



	%TGI	PR/CR
● Vehicle	---	---
■ 10mg/kg Compound 2 PO, QD	65	0/0
▲ 30mg/kg Compound 2 PO, QD	91	9/0
▼ 3mg/kg Cetuximab IP, BIW	73	0/0
□ 10mg/kg Compound 2 + Cetuximab	93	9/1
△ 30mg/kg Compound 2 + Cetuximab	98	3/7

Mice bearing subcutaneous LS513 (colorectal cancer) xenograft tumors were treated with $\pm$ INCB186748 $\pm$ cetuximab
Note 1: #10 mg/kg Compound 2 + Cetuximab vs. monotherapy groups (10 mg/kg Compound 2 or cetuximab) (p $\leq$ 0.0008)
Note 2: &- 30 mg/kg Compound 2 + Cetuximab vs. monotherapy groups (30 mg/kg Compound 2 or cetuximab) (p $\leq$ 0.0003)

FIG. 4

FIG. 5

